Pneumococcal 20-valent conjugate vaccine


Entry
D12207                      Drug                                   
Name
Pneumococcal 20-valent conjugate vaccine;
Prevnar 20 (TN);
Apexxnar (TN)
Product
PREVNAR 20 (Wyeth Pharmaceutical Division of Wyeth Holdings LLC)
Class
Vaccine
 DG01686  Inactivated vaccine
Remark
ATC code: J07AL02
Product: D12207<US>
Efficacy
Active immunization (pneumococcal)
  Disease
Prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F [DS:H01321]
Comment
Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J07 VACCINES
   J07A BACTERIAL VACCINES
    J07AL Pneumococcal vaccines
     J07AL02 Pneumococcus, purified polysaccharides antigen conjugated
      D12207  Pneumococcal 20-valent conjugate vaccine <US>
USP drug classification [BR:br08302]
 Immunological Agents
  Vaccines
   Pneumococcal
    Pneumococcal 20-Valent Conjugate Vaccine
     D12207  Pneumococcal 20-valent conjugate vaccine
Drug groups [BR:br08330]
 Vaccine
  DG01686  Inactivated vaccine
   D12207  Pneumococcal 20-valent conjugate vaccine
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12207
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12207
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12207